Abstract
Major depressive disorder (MDD) is generally classified as a mood disorder with a profound effect on the individual’s behavior and quality of life. According to the World Health Organization, in about 20 years, depression will be the disorder with the most significant repercussions, both socially and economically. Despite the substantial progress in the development of new antidepressants, their effectiveness remains low, with remission of about 50 % after a single regime of treatment. The most common form of pharmacological treatment of MDD is based on selective serotonin reuptake inhibitors (SSRIs), designed to increase extracellular levels of the neurotransmitter serotonin. Unfortunately, antidepressants currently available based on SSRIs may take several weeks to achieve the desired therapeutic effects. Therefore, massive effort has been devoted to find alternative treatments for MDD. For example, the use of ketamine, of (±)-1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI), and β-carbolines is under current investigation. Based on evidence from the literature and a pilot study conducted by our group, we speculate about the possible therapeutic potential of ayahuasca for MDD. In part, such conjecture is based on the fact that ayahuasca combines N,N-dimethyltryptamine (DMT), acting particularly on serotonin neurotransmission through 5-HT2A receptors and monoamine oxidase inhibitors (MAOI), both involved, at least indirectly, with pharmacological formulations intended for MDD treatment. In this chapter, we will review the major aspects of MDD such as diagnosis, current pharmacological treatments, and the motivations to use ayahuasca as a novel alternative.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
American Psychiatric Association. (2000a). American Psychiatric Association practice guidelines for the treatment of psychiatric disorders: Compendium 2000. Washington, DC: Author.
American Psychiatric Association. (2000b). Diagnostic criteria from DSM-IV-TR. Arlington, VA: Author.
Anand, A., Li, Y., Wang, Y., Wu, J., Gao, S., Bukhari, L., Mathews, V. P., et al. (2005). Antidepressant effect on connectivity of the mood-regulating circuit: An FMRI study. Neuropsychopharmacology, 30(7), 1334–1344. doi:1300725 [pii] 10.1038/sj.npp.1300725.
Andrade, P., Noblesse, L. H., Temel, Y., Ackermans, L., Lim, L. W., Steinbusch, H. W., et al. (2010). Neurostimulatory and ablative treatment options in major depressive disorder: A systematic review. Acta Neurochir (Wien), 152(4), 565–577. doi:10.1007/s00701-009-0589-6.
Aricioglu, F., & Altunbas, H. (2003). Harmane induces anxiolysis and antidepressant-like effects in rats. Annals of the New York Academy of Sciences, 1009, 196–201.
Asnis, G. M., Halbreich, U., Sachar, E. J., Nathan, R. S., Ostrow, L. C., Novacenko, H., et al. (1983). Plasma cortisol secretion and REM period latency in adult endogenous depression. American Journal of Psychiatry, 140(6), 750–753.
Barbanoj, M. J., Riba, J., Clos, S., Gimenez, S., Grasa, E., & Romero, S. (2008). Daytime ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers. Psychopharmacology, 196(2), 315–326. doi:10.1007/S00213-007-0963-0.
Benca, R. M., Obermeyer, W. H., Thisted, R. A., & Gillin, J. C. (1992). Sleep and psychiatric disorders: A meta-analysis. Archives of General Psychiatry, 49(8), 651–668 (discussion 669–670).
Berry, A., Bellisario, V., Capoccia, S., Tirassa, P., Calza, A., Alleva, E., et al. (2012). Social deprivation stress is a triggering factor for the emergence of anxiety-and depression-like behaviours and leads to reduced brain BDNF levels in C57BL/6 J mice. Psychoneuroendocrinology, 37(6), 762–772.
Boland, R. J., & Keller, M. B. (2004). Antidepressants. In A. F. Schatzberg & C. B. Nemeroff (Eds.), Textbook of Psychopharmacology (3rd ed., pp. 847–864). Washington, DC: American Psychiatric Press.
Bremner, J. D., Narayan, M., Anderson, E. R., Staib, L. H., Miller, H. L., & Charney, D. S. (2000). Hippocampal volume reduction in major depression. American Journal of Psychiatry, 157(1), 115–117.
Buckner, R. L., Andrews-Hanna, J. R., & Schacter, D. L. (2008). The brain’s default network: Anatomy, function, and relevance to disease. Annals of the New York Academy of Sciences, 1124, 1–38. doi:1124/1/1 [pii] 10.1196/annals.1440.011.
Callaway, J. C., McKenna, D. J., Grob, C. S., Brito, G. S., Raymon, L. P., Poland, R. E., et al. (1999). Pharmacokinetics of Hoasca alkaloids in healthy humans. Journal of Ethnopharmacology, 65(3), 243–256.
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P. T., Churchill, R., et al. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis. Lancet, 373(9665), 746–758. doi:10.1016/s0140-6736(09)60046-5.
Cozzi, N. V., Gopalakrishnan, A., Anderson, L. L., Feih, J. T., Shulgin, A. T., Daley, P. F., et al. (2009). Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. Journal of Neural Transmission, 116(12), 1591–1599.
Cuijpers, P., Geraedts, A. S., van Oppen, P., Andersson, G., Markowitz, J. C., & van Straten, A. (2011). Interpersonal psychotherapy for depression: A meta-analysis. American Journal of Psychiatry, 168(6), 581–592. doi:appi.ajp.2010.10101411 [pii] 10.1176/appi.ajp.2010.10101411.
Davey, C. G., Allen, N. B., Harrison, B. J., & Yucel, M. (2011). Increased amygdala response to positive social feedback in young people with major depressive disorder. Biological Psychiatry, 69(8), 734–741. doi:S0006–3223(10)01275–8 [pii] 10.1016/j.biopsych.2010.12.004.
de Araujo, D. B., Ribeiro, S., Cecchi, G. A., Carvalho, F. M., Sanchez, T. A., Pinto, J. P., et al. (2011). Seeing with the eyes shut: Neural basis of enhanced imagery following ayahuasca ingestion. Human Brain Map**, 33(11), 2550–2560. doi:10.1002/hbm.21381.
de Lima Osório, F., de Macedo, L. R. H., de Sousa, J. P. M., Pinto, J. P., Quevedo, J., de Souza Crippa, J. A., et al. (2011). The therapeutic potential of harmine and ayahuasca in depression: Evidence from exploratory animal and human studies. In R. E. Dos Santos (Ed.), The ethnopharmacology of ayahuasca (pp. 75–85). Trivandrum, India: Transworld Research Network.
Devilbiss, D. M., Jenison, R. L., & Berridge, C. W. (2012). Stress-induced impairment of a working memory task: Role of spiking rate and spiking history predicted discharge. PLoS Computational Biology, 8(9), e1002681.
Dhonnchadha, B., Bourin, M., & Hascoet, M. (2003). Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety. Behavioural Brain Research, 140(1–2), 203–214. doi:PII S0166–4328(02)00311-X.
Dos Santos, R. G., Grasa, E., Valle, M., Ballester, M. R., Bouso, J. C., Nomdedéu, J. F., et al. (2012). Pharmacology of ayahuasca administered in two repeated doses. Psychopharmacology (Berl), 219(4), 1039–1053. doi: 10.1007/s00213-011-2434-x.
Dos Santos, R. G., Valle, M., Bouso, J. C., Nomdedéu, J. F., Rodríguez-Espinosa, J., McIlhenny, E. H., et al. (2011). Autonomic, neuroendocrine, and immunological effects of ayahuasca: A comparative study with d-amphetamine. Journal of Clinical Psychopharmacology, 31(6), 717–726. doi:10.1097/JCP.0b013e31823607f6.
Dziurkowska, E., Wesolowski, M., & Dziurkowski, M. (2013). Salivary cortisol in women with major depressive disorder under selective serotonin reuptake inhibitors therapy. Archives of Women’s Mental Health, 16(2), 139–147. doi:10.1007/s00737-013-0329-z.
Ebmeier, K., Donaghey, C., & Steele, J. (2006). Recent developments and current controversies in depression. Lancet, 367(9505), 153–167.
Farzin, D., & Mansouri, M. (2005). Anti-immobility effects of beta-carbolines in the mouse forced-swim test. Behavioural Pharmacology, 16, S41–S42.
Fava, M., & Kendler, K. (2000). Major depressive disorder. Neuron, 28(2), 335–341.
Fontes, F. P., Ribeiro, S. T. G., Pinto, J. P., Hallak, J. E. C., Crippa, J. A. S., & De Araujo, D. B. (2012). Default Mode Network changes induced by ayahuasca. New Orleans, LA: Paper presented at the Society for Neuroscience Annual Meeting.
Fortunato, J. J., Réus, G. Z., Kirsch, T. R., Stringari, R. B., Fries, G. R., Kapczinski, F., et al. (2010). Effects of beta-carboline harmine on behavioral and physiological parameters observed in the chronic mild stress model: Further evidence of antidepressant properties. Brain Research Bulletin, 81(4–5), 491–496. doi:S0361–9230(09)00304–9 [pii] 10.1016/j.brainresbull.2009.09.008.
Fábregas, J. M., González, D., Fondevila, S., Cutchet, M., Fernández, X., Barbosa, P. C. R., et al. (2010). Assessment of addiction severity among ritual users of ayahuasca. Drug and Alcohol Dependence, 111(3), 257–261.
Giles, D. E., Biggs, M. M., Rush, A. J., & Roffwarg, H. P. (1988). Risk factors in families of unipolar depression. I. Psychiatric illness and reduced REM latency. Journal of Affective Disorders, 14(1), 51–59.
Giles, D. E., Kupfer, D. J., Roffwarg, H. P., Rush, A. J., Biggs, M. M., & Etzel, B. A. (1989). Polysomnographic parameters in first-degree relatives of unipolar probands. Psychiatry Research, 27(2), 127–136.
Giles, D. E., Roffwarg, H. P., & Rush, A. J. (1987). REM latency concordance in depressed family members. Biological Psychiatry, 22(7), 910–914. doi:0006–3223(87)90090–4 [pii].
Grady, M. M., & Stahl, S. M. (2012). Practical guide for prescribing MAOIs: Debunking myths and removing barriers. CNS Spectrums, 17(1), 2–10. doi:10.1017/S109285291200003X.
Greicius, M. D., Flores, B. H., Menon, V., Glover, G. H., Solvason, H. B., Kenna, H., et al. (2007). Resting-state functional connectivity in major depression: Abnormally increased contributions from subgenual cingulate cortex and thalamus. Biological Psychiatry, 62(5), 429–437. doi:10.1016/j.biopsych.2006.09.020.
Grob, C., McKenna, D., Callaway, J., Brito, G., Neves, E., Oberlaender, G., et al. (1996). Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. Journal of Nervous and Mental Disease, 184(2), 86–94.
Jacob, M., & Presti, D. (2005). Endogenous psychoactive tryptamines reconsidered: An anxiolytic role for dimethyltryptamine. Medical Hypotheses, 64(5), 930–937. doi:10.1016/j.mehy.2004.11.005.
Kennedy, S., Lam, R., Cohen, N., Ravindran, A., & CANMAT Depression Workgroup (2001). Clinical guidelines for the treatment of depressive disorders IV. Medications and other biological treatments. Canadian Journal of Psychiatry, 46,(Suppl. 1), 38S–58S.
Knorr, U., Vinberg, M., Kessing, L. V., & Wetterslev, J. (2010). Salivary cortisol in depressed patients versus control persons: A systematic review and meta-analysis. Psychoneuroendocrinology, 35(9), 1275–1286. doi:10.1016/j.psyneuen.2010.04.001.
Lakhan, S. E., Vieira, K., & Hamlat, E. (2010). Biomarkers in psychiatry: Drawbacks and potential for misuse. International Archives of Medicine, 3(1). doi:10.1186/1755-7682-3-1.
Lauer, C. J., Schreiber, W., Holsboer, F., & Krieg, J. C. (1995). In quest of identifying vulnerability markers for psychiatric disorders by all-night polysomnography. Archives of General Psychiatry, 52(2), 145–153.
Leonard, B. E. (2007). Inflammation, depression, and dementia: Are they connected? Neurochemical Research, 32(10), 1749–1756. doi:10.1007/s11064-007-9385-y.
Leuchter, A. F., Cook, I. A., Hamilton, S. P., Narr, K. L., Toga, A., Hunter, A. M., et al. (2010). Biomarkers to predict antidepressant response. Current Psychiatry Reports, 12(6), 553–562. doi:10.1007/s11920-010-0160-4.
Li, M., Soczynska, J. K., & Kennedy, S. H. (2011). Inflammatory biomarkers in depression: An opportunity for novel therapeutic interventions. Curr Psychiatry Rep, 13(5), 316–320. doi:10.1007/s11920-011-0210-6.
Liebrenz, M., Borgeat, A., Leisinger, R., & Stohler, R. (2007). Intravenous ketamine therapy in a patient with a treatment-resistant major depression. Swiss Medical Weekly, 137(15–16), 234–236.
Lorenzetti, V., Allen, N. B., Fornito, A., & Yucel, M. (2009). Structural brain abnormalities in major depressive disorder: A selective review of recent MRI studies. Journal of Affective Disorders, 117(1–2), 1–17. doi:S0165-0327(08)00476-X [pii] 10.1016/j.jad.2008.11.021.
MacQueen, G. M. (2009). Magnetic resonance imaging and prediction of outcome in patients with major depressive disorder. Journal of Psychiatry and Neuroscience, 34(5), 343–349.
Mannie, Z. N., Harmer, C. J., & Cowen, P. J. (2007). Increased waking salivary cortisol levels in young people at familial risk of depression. American Journal of Psychiatry, 164(4), 617–621. doi:164/4/617 [pii] 10.1176/appi.ajp.164.4.617.
Masuda, Y., & Sugiyama, T. (2000). The effect of globopentaosylceramide on a depression model, mouse forced swimming. Tohoku Journal of Experimental Medicine, 191(1), 47–54.
McKenna, D. J. (2004). Clinical investigations of the therapeutic potential of ayahuasca: Rationale and regulatory challenges. Pharmacology & Therapeutics, 102(2), 111–129.doi:2004/03/002 [pii] 10.1016/J.Pharmathera.2004.03.002.
McKenna, D. J., Towers, G. H., & Abbott, F. S. (1984). Monoamine oxidase inhibitors in South American hallucinogenic plants part 2: Constituents of orally-active myristicaceous hallucinogens. Journal of Ethnopharmacology, 12(2), 179–211. doi:0378-8741(84)90048-5
Miura, H., Ozaki, N., Sawada, M., Isobe, K., Ohta, T., & Nagatsu, T. (2008). A link between stress and depression: Shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression. Stress: The International Journal on the Biology of Stress, 11(3), 198–209.
Northoff, G., Heinzel, A., Greck, M., Bennpohl, F., Dobrowolny, H., & Panksepp, J. (2006). Self-referential processing in our brain: A meta-analysis of imaging studies on the self. Neuroimage, 31(1), 440–457. doi:10.1016/J.Neuroimage.2005.12.002.
Pace, T. W., Hu, F., & Miller, A. H. (2007). Cytokine-effects on glucocorticoid receptor function: Relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain, Behavior, and Immunity, 21(1), 9–19. doi:10.1016/j.bbi.2006.08.009.
Pariante, C. M., Thomas, S. A., Lovestone, S., Makoff, A., & Kerwin, R. W. (2004). Do antidepressants regulate how cortisol affects the brain? Psychoneuroendocrinology, 29(4), 423–447.
Pivac, N., Mück-Seler, D., Sagud, M., & Jakovljević, M. (2002). Platelet serotonergic markers in posttraumatic stress disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 26(6), 1193–1198. doi:S0278-5846(02)00261-0 [pii].
Poland, R. E., McCracken, J. T., Lutchmansingh, P., & Tondo, L. (1992). Relationship between REM sleep latency and nocturnal cortisol concentrations in depressed patients. Journal of Sleep Research, 1(1), 54–57.
Prado, D. A., Pinto, J., Crippa, J., Santos, A., Ribeiro, S., Araujo, D., et al. (2009). Effects of the Amazonian psychoactive plant beverage ayahuasca on prefrontal and limbic regions during a language task: An fMRI study. European Neuropsychopharmacology, 19, S314–S315.
Raichle, M. E., MacLeod, A. M., Snyder, A. Z., Powers, W. J., Gusnard, D. A., & Shulman, G. L. (2001). A default mode of brain function. Proceedings of the National Academy of Sciences of the United States of America, 98(2), 676–682.
Riba, J., Rodriguez-Fornells, A., Urbano, G., Morte, A., Antonijoan, R., Montero, M., et al. (2001). Subjective effects and tolerability of the South American psychoactive beverage ayahuasca in healthy volunteers. Psychopharmacology, 154(1), 85–95.
Riba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., & Barbanoj, M. J. (2003). Human pharmacology of ayahuasca: Subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics, 306(1), 73–83. doi:10.1124/Jpet.103.049882.
Riemann, D., Berger, M., & Voderholzer, U. (2001). Sleep and depression—results from psychobiological studies: An overview. Biological Psychology, 57(1–3), 67–103.
Santos, R. G., Landeira-Fernandez, J., Strassman, R. J., Motta, V., & Cruz, A. P. M. (2007). Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. Journal of Ethnopharmacology, 112(3), 507–513. doi:10.1016/J.Jep.2007.04.012.
Sapolsky, R. M. (2004). Is impaired neurogenesis relevant to the affective symptoms of depression? Biological Psychiatry, 56(3), 137–139.
Schüle, C. (2006). Neuroendocrinological mechanisms of actions of antidepressant drugs. Journal of Neuroendocrinology, 19(3), 213–226.
Schüle, C., Baghai, T. C., Eser, D., Zwanzger, P., Jordan, M., Buechs, R., et al. (2006). Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients. Psychopharmacology (Berl), 186(4), 601–611.
Segal, Z. V., Bieling, P., Young, T., MacQueen, G., Cooke, R., Martin, L., et al. (2010). Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression. Archives of General Psychiatry, 67(12), 1256–1264. doi:67/12/1256 [pii] 10.1001/archgenpsychiatry.2010.168.
Shanon, B. (2003). Altered states and the study of consciousness: The case of ayahuasca. Journal of Mind and Behavior, 24(2), 125–153.
Sheline, Y. I., Barch, D. M., Donnelly, J. M., Ollinger, J. M., Snyder, A. Z., & Mintun, M. A. (2001). Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: An fMRI study. Biological Psychiatry, 50(9), 651–658. doi:S000632230101263X [pii].
Sheline, Y. I., Barch, D. M., Price, J. L., Rundle, M. M., Vaishnavi, S. N., Snyder, A. Z., et al. (2009). The Default Mode Network and self-referential processes in depression. Proceedings of the National Academy of Sciences USA, 106(6), 1942–1947. doi:0812686106 [pii] 10.1073/pnas.0812686106.
Sheline, Y. I., Price, J. L., Yan, Z. Z., & Mintun, M. A. (2010). Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus. Proceedings of the National Academy of Sciences of the United States of America, 107(24), 11020–11025. doi:10.1073/Pnas.1000446107.
Shimizu, E., Hashimoto, K., Okamura, N., Koike, K., Komatsu, N., Kumakiri, C., et al. (2003). Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biological Psychiatry, 54(1), 70–75.
Su, T. P., Hayashi, T., & Vaupel, D. B. (2009). When the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the sigma-1 receptor. Science Signaling, 2(61), pe12.
Tadić, A., Wagner, S., Gorbulev, S., Dahmen, N., Hiemke, C., Braus, D. F., & Lieb, K. (2011). Peripheral blood and neuropsychological markers for the onset of action of antidepressant drugs in patients with Major Depressive Disorder. BMC Psychiatry, 11, 16. doi:1471-244X-11-16 [pii] 10.1186/1471-244X-11-16.
Tsuno, N., Besset, A., & Ritchie, K. (2005). Sleep and depression. Journal of Clinical Psychiatry, 66(10), 1254–1269.
Uppal, A., Singh, A., Gahtori, P., Ghosh, S. K., & Ahmad, M. Z. (2010). Antidepressants: Current strategies and future opportunities. Current Pharmaceutical Design, 16(38), 4243–4253. doi:BSP/CPD/E-Pub/000292 [pii].
Veer, I. M., Beckmann, C. F., van Tol, M. J., Ferrarini, L., Milles, J., Veltman, D. J., et al. (2010). Whole brain resting-state analysis reveals decreased functional connectivity in major depression. Frontiers in Systems Neuroscience, 4. doi:10.3389/fnsys.2010.00041.
Warden, D., Rush, A. J., Trivedi, M. H., Fava, M., & Wisniewski, S. R. (2007). The STAR*D Project results: A comprehensive review of findings. Current Psychiatry Reports, 9(6), 449–459.
Wong, M., & Licinio, J. (2001). Research and treatment approaches to depression. Nature Reviews Neuroscience, 2(5), 343–351.
Zarate, C. (2011). A randomized trial of an N-methyl-D-aspartate antagonist and neural correlates of rapid antidepressant response in treatment-resistant bipolar depression. Biological Psychiatry, 69(9), 115S–115S.
Zarate, C., Singh, J., Carlson, P., Brutsche, N., Ameli, R., Luckenbaugh, D., et al. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry, 63(8), 856–864.
Zhou, J., Li, L., Tang, S., Cao, X., Li, Z., Li, W., et al. (2008). Effects of serotonin depletion on the hippocampal GR/MR and BDNF expression during the stress adaptation. Behavioural Brain Research, 195(1), 129–138.
Zunszain, P. A., Anacker, C., Cattaneo, A., Carvalho, L. A., & Pariante, C. M. (2011). Glucocorticoids, cytokines, and brain abnormalities in depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35(3), 722–729. doi:10.1016/j.pnpbp.2010.04.011.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Palhano-Fontes, F. et al. (2014). The Therapeutic Potentials of Ayahuasca in the Treatment of Depression. In: Labate, B.C., Cavnar, C. (eds) The Therapeutic Use of Ayahuasca. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-40426-9_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-40426-9_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-40425-2
Online ISBN: 978-3-642-40426-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)